about
Elafin is a biomarker of graft-versus-host disease of the skinMaking the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantationSuccessful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H.Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialLower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.Less (bacterial diversity) is more (deaths)Pathogenesis and management of graft-versus-host disease.Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.Plasma biomarkers of lower gastrointestinal and liver acute GVHD.Malignant triton tumor in a patient with Li-Fraumeni syndrome and a novel TP53 mutation.Implications of TNF-α in the pathogenesis and management of GVHDUse of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive CommittExtramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomesUnrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.A biomarker panel for acute graft-versus-host diseaseLow Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortalityThe impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors.Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.Plasma biomarkers in graft-versus-host disease: a new era?Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.Hematopoietic stem cell transplantation for severe congenital neutropenia.Impact of psychological screening on routine outpatient care of hematopoietic cell transplantation survivorsPilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkVaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.Acute renal failure following deferoxamine overdose.Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit.Reduced intensity versus full myeloablative stem cell transplant for advanced CLL.Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline.Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
P50
Q24622918-D5623630-FCF3-4712-8910-5A023300AF04Q27002964-995996D2-4A0A-4F42-82EE-CE85D23C5CD8Q33374837-982F406D-8A6F-4963-8508-3298FDE2A4B1Q33411822-51488272-D351-428D-BA50-CA667EF8920BQ33718833-F6EF449E-9ADD-4EE9-8C43-46E740E56673Q33783145-A28A58D2-8ECB-4BE4-9512-D302B9124F39Q34047945-33DE927D-2934-4AB8-A835-524B1E9CB4DFQ34077479-EDC5682B-F974-4E00-B50C-F052E5D008E0Q34079430-D696ACEC-713C-4359-8A02-02E914FF571CQ34093615-B0E38340-9DC7-4320-8C5B-586284059CF7Q34607576-B68E3E6C-CB9C-4FEA-B642-C80578B43B65Q35623673-086BFDA4-17A0-4D62-9094-86696C11B23CQ35714438-6EC7C108-C664-4384-A7A4-10CBC3281DDCQ35891657-ED2976C8-6219-4EF5-9570-B64EAA23B786Q36333668-ABB08686-061C-4EDB-AC5A-51A649371E7CQ36370782-231E096A-E430-49CB-8B23-7623E0E06CEFQ36389445-FC786CF6-B479-4035-A838-ECBD790A821AQ36579060-0A929C0F-3762-4B9E-BAF5-6EB7D7AF40E8Q36745209-CDDCB34A-762B-4318-8C5B-4FA2AC2F2E02Q36835126-C3E5D571-2D28-4D48-B7B6-9631894718BAQ36841805-E08BD312-8857-4F75-856E-D71BB3FE280EQ37041904-89B526DD-EB3D-4717-8B23-550078E49328Q37113096-00F703F7-9F00-4F5C-999B-FEF3188D8A7BQ37138616-04F3992C-83F1-4F36-BBCE-CFDE70EB39FCQ37152028-499DEC35-6E23-4E82-B9CA-6C9ADCC01CAEQ37369393-63A04E12-CB5D-49C1-A419-0801E24F8E77Q37535273-82B1B8C8-54CB-4DC6-926B-9DE98132B3E2Q37955726-F00009E1-66BA-4D37-A182-FDDE1D12D64BQ39376991-EEBA309A-C1F2-419D-BD1C-AD3FE9257FA2Q40646280-AC756003-2781-417F-8D08-CFD4557B7C1EQ42149848-4DAD02C4-98B6-4482-9CE2-27A621A8EAB6Q43814408-6E3F7006-B0B8-4B09-A933-BBBF6D5C1C68Q44367503-B4486BA9-4B43-44B5-B31C-137D70E5525CQ45405621-2F797BE8-BBF5-4316-B963-05BC7DCF95DEQ46077879-27079175-6EBC-4120-BD1D-18ADDA9F452EQ46265392-CE54E6FC-FEC5-47A8-8C75-D58342473822Q46672540-AC8EB5D0-227C-4535-B5B6-7F5019C518D7Q46674272-B0427A88-5B5A-4DAB-92EA-2520CF363A3FQ48833503-5448D1BC-0875-4585-BE92-2B674EB1BD45Q52006825-31763A10-F01B-458D-B184-41F92EC87793
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John E Levine
@ast
John E Levine
@en
John E Levine
@es
John E Levine
@nl
type
label
John E Levine
@ast
John E Levine
@en
John E Levine
@es
John E Levine
@nl
prefLabel
John E Levine
@ast
John E Levine
@en
John E Levine
@es
John E Levine
@nl
P106
P1153
56055217500
P31
P496
0000-0002-9133-0800